Functional differences between low- and high-affinity CD8+ T cells in the tumor environment

Weak T-cell antigen receptor (TCR)-ligand interactions are sufficient to activate naïve CD8 + T cells, but generally do not result in tumor eradication. How differences in TCR affinity affect the regulation of T-cell function in an immunosuppressive tumor environment has not been investigated. We ha...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 1; no. 8; pp. 1239 - 1247
Main Authors Bos, Rinke, Marquardt, Kristi L., Cheung, Jocelyn, Sherman, Linda A.
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.11.2012
Landes Bioscience
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Weak T-cell antigen receptor (TCR)-ligand interactions are sufficient to activate naïve CD8 + T cells, but generally do not result in tumor eradication. How differences in TCR affinity affect the regulation of T-cell function in an immunosuppressive tumor environment has not been investigated. We have examined the functional differences of high- vs. low-affinity CD8 + T cells and we observed that infiltration, accumulation, survival and cytotoxicity within the tumor are severely impacted by the strength of TCR-ligand interactions. In addition, high-affinity CD8 + T cells were found to exhibit lower expression of inhibitory molecules including PD-1, LAG-3 and NKG2A, thus being less susceptible to suppressive mechanisms. Interferon γ and autocrine interleukin-2 were both found to influence the level of expression of these molecules. Interestingly, although high-affinity CD8 + T cells were superior to low-affinity CD8 + T cells in their ability to effect tumor eradication, they could be further improved by the presence of tumor specific CD4 + T cells. These findings illustrate the importance of both TCR affinity and tumor-specific CD4 help in tumor immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.4161/onci.21285